Oncogene
p21-dependent cell cycle arrest guards against unrestricted cell proliferation
Published in Blood Weekly, August 5th, 2004
According to recent research from the United States, "p21 is a potent inhibitor of cyclin-dependent kinases capable of arresting cell cycle progression. p21 is primarily regulated at the transcriptional level by several transcription factors, including p53."
"Previously," wrote S.K. Radhakrishnan, "we reported that certain members of the E2F family of transcription factors may activate p21 transcription via a p53-independent mechanism. To further elucidate the consequences of E2F-1-regulated induction of p21, we developed cell lines with a tamoxifen-dependent form of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-08-05)
More Articles from Blood Weekly
- Hematologic Disease
Hepatitis C virus associates with thrombocytopenia formation - Hematology
Single recombinant anti-RhD IgG prevents RhD immunization - Stem Cell Transplantation
Donor treatment with pegylated G-CSF promotes transplantation tolerance - Stem Cell Transplantation
IL-10/TNF alpha region haplotypes predict mortality after unrelated donor SCT - Stem Cell Transplantation
Steroid and cyclosporine A use are risk factors for bone loss following SCT - Acute Lymphoblastic Leukemia
Novel FLT3 inhibitors may be considered to treat hyperdiploid or relapsed ALL - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
